Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02436993
Title Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors University of California, Irvine

breast carcinoma



Pertuzumab + Trastuzumab

Carboplatin + Paclitaxel

Age Groups: adult
Covered Countries USA

No variant requirements are available.